Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Authors' conclusion
Although the primary endpoint did not meet the prespecified significance level, these data suggest that astaxanthin is a safe over-the-counter supplement that improves lipid profiles and markers of CVD risk in individuals with prediabetes and dyslipidaemia.
Study context
- Population
- Adults with dyslipidaemia and prediabetes
- Participants
- 34 adults
- Comparison
- Astaxanthin 12 mg daily vs placebo for 24 weeks
- Astaxanthinn = 22
- Placebon = 12reference
- Primary endpoint
- Insulin-stimulated, whole-body glucose disposal (hyperinsulinaemic-euglycaemic clamp)
- Follow-up
- 24 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Insulin-stimulated, whole-body glucose disposal, change with astaxanthin
Change with astaxanthin (trend, not significant), P = .078
+0.52 ± 0.37 mg/m² /min
Further findings
Lipids, change with astaxanthin · 24 weeks
- LDL (P < .05)
- −0.33 ± 0.11 mM
- Total cholesterol (P < .05)
- −0.30 ± 0.14 mM
Cardiovascular disease (CVD) risk markers, change with astaxanthin · 24 weeks
- Fibrinogen (P < .05)
- −473 ± 210 ng/mL
- L-selectin (P < .05)
- −0.08 ± 0.03 ng/mL
- Fetuin-A (P < .05)
- −10.3 ± 3.6 ng/mL
Insulin action, change with astaxanthin (trends) · 24 weeks
- Fasting insulin, P = .097
- −5.6 ± 8.4 pM
- HOMA2-IR, P = .060
- −0.31 ± 0.16
Placebo
- No consistent significant differences from baseline for any of these outcomes with placebo
Safety
- Astaxanthin was safe and well tolerated with no clinically significant adverse events
Original publication
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia. Diabetes Obes Metab. Published 20 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →